Humulin N (Insulin Human (Rdna))

Humulin N is used as a basal (long‑acting) insulin to control blood glucose in diabetes.

• Type 1 diabetes mellitus as part of a basal‑bolus regimen.
• Type 2 diabetes mellitus when oral agents are insufficient.
• Adjunct therapy for patients requiring stable overnight glucose control.
• Combination with rapid‑acting insulin for full‑day coverage.
• May be used during pregnancy only under specialist supervision if indicated.

• Humulin N contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering endogenous glucose production and contributing to overall glycemic control.

Like other insulin preparations, Humulin N may cause injection‑site reactions and systemic effects related to hypoglycemia.

Common

• Low blood sugar (hypoglycemia) presenting as sweating, tremor, or confusion.
• Redness, swelling, or itching at the injection site.
• Weight gain associated with improved glucose utilization.
• Lipodystrophy (localized fat accumulation or loss) at repeated injection sites.
• Bruising or bleeding at injection site.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Hypokalemia secondary to insulin‑driven cellular uptake of potassium.
• Anaphylactic shock requiring immediate medical attention.

Before initiating Humulin N, clinicians should evaluate patient history and monitor several clinical parameters to reduce risk.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review history of hypoglycemia unawareness or severe episodes.
• Adjust dose when starting or stopping concomitant glucocorticoids, beta‑blockers, or diuretics.
• Educate patients on proper injection technique and rotation of sites.
• Advise regular blood glucose monitoring, especially during illness or changes in diet.
• Consider pregnancy status; insulin is the preferred agent but requires specialist guidance.

Humulin N can interact with several medications that affect glucose metabolism or insulin pharmacodynamics.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which may cause severe hypoglycemia.
• MAO‑B inhibitors (e.g., selegiline) that potentiate insulin’s glucose‑lowering effect.
• High‑dose salicylates that may increase insulin sensitivity and risk of hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Corticosteroids, which can raise blood glucose and require higher insulin doses.
• Thiazide diuretics, which may increase serum potassium shifts and affect glucose control.